Jonas J

2023.09.05

I-Mab Announces Upcoming Participation at September Conferences

2023.08.17

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

2023.08.08

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

2023.07.05

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

2023.06.22

I-Mab Announces the Appointment of Raj Kannan as CEO

2023.05.26

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

2023.04.26

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

2023.04.25

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

2023.04.24

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

2023.03.31

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022